Status:
NOT_YET_RECRUITING
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
Lead Sponsor:
AstraZeneca
Conditions:
Moderate to Severe COPD
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
Detailed Description
Study details include: The study duration will be 26 weeks The treatment duration will be 24 weeks
Eligibility Criteria
Inclusion
- Patients with a physician-confirmed diagnosis of COPD
- With a history of one severe COPD exacerbation or two or more moderate COPD exacerbations in the preceding 12 months.
- Post-bronchodilator FEV1 should be between ≥30 % to \<80% of the predicted normal.
- Both male and female patients are allowed in the study
- Female of Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal)
- A urine pregnancy test must be negative at screening.
- female participant must follow effective contraceptive method as outlined in protocol
- Patients should be capable of giving signed informed consent
Exclusion
- Significant diseases or conditions other than COPD, which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
- Chest x-ray within 6 months before screening must be acceptable to the investigator. Subjects who have a chest x-ray that reveals clinically significant abnormalities not believed to be due to the presence of COPD should not be included. A chest x-ray must be conducted if the most recent chest x-ray is not available at the time of screening.
- Patients having moderate to severe exacerbations within 6 weeks before the Screening period.
- Female patients who are pregnant or lactating or planning a family during the study period.
- Patients with either a history of hypersensitivity to excipients of the study drug or drugs with a similar chemical structure or class to the study drug.
- Patients participating in any current or future interventional trial during the study will not be enrolled in the current study.
Key Trial Info
Start Date :
December 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06531798
Start Date
December 30 2025
End Date
December 30 2027
Last Update
October 30 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.